Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRB | P28702 | 2/20 | 0.49 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28370258 | 0.86 | POLB (0.43) | RXRBALDH1A1NR1H4KDM4ETDP1 | |
| SCHEMBL966871 | 0.84 | RXRB (0.50) | RXRBRXRAHTTALDH1A1AKR1C2 | |
| SCHEMBL14786372 | 0.83 | ELANE (0.40) | RXRAHTT | |
| SCHEMBL12951604 | 0.82 | SRD5A2 (0.52) | HTTALDH1A1KDM4EPOLB | |
| SCHEMBL7623240 | 0.81 | POLB (0.54) | RXRBRXRAHTTALDH1A1NR1H4 | |
| SCHEMBL2592316 | 0.81 | RARB (0.45) | RXRAALDH1A1NR1H4KDM4E | |
| SCHEMBL634335 | 0.79 | HTT (0.65) | HTTALDH1A1KDM4EAKR1C3AKR1C2 | |
| SCHEMBL2588369 | 0.79 | ALDH1A1 (0.56) | HTTALDH1A1KDM4ETDP1AKR1C3 | |
| SCHEMBL3301071 | 0.79 | ALDH1A1 (0.51) | RXRBRXRAHTTALDH1A1KDM4E | |
| SCHEMBL3950221 | 0.79 | CSNK2A1 (0.52) | HTTALDH1A1KDM4ETDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070946-A1 | Hydroxymethylbenzothiazoles Amides | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | US | claimed |
| EP-1799661-A1 | NEW HYDROXYMETHYLBENZOTHIAZOLES AMIDES | AstraZeneca AB (SE) | 2007-06-27 | — | — | EP | claimed |
| WO-2006038871-A1 | NEW HYDROXYMETHYLBENZOTHIAZOLES AMIDES | ASTRAZENECA AB (SE) | 2006-04-13 | — | — | WO | claimed |
| US-9527830-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2016-12-27 | — | — | US | disclosed |
| EP-2755656-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2016-09-07 | — | — | EP | disclosed |
| US-20140235628-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | MERCK SHARP & DOHME LLC | 2014-08-21 | — | — | US | disclosed |
| EP-2755656-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2014-07-23 | — | — | EP | disclosed |
| WO-2013039802-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2013-03-21 | — | — | WO | disclosed |
| US-20080070946-A1 | Hydroxymethylbenzothiazoles Amides | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | US | disclosed |
| EP-1799661-A1 | NEW HYDROXYMETHYLBENZOTHIAZOLES AMIDES | AstraZeneca AB (SE) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006038871-A1 | NEW HYDROXYMETHYLBENZOTHIAZOLES AMIDES | ASTRAZENECA AB (SE) | 2006-04-13 | — | — | WO | disclosed |
| US-RE30812-E | ANTIARRHTHMIA AGENTS | MEAD JOHNSON & COMPANY (US) | 1981-12-01 | — | — | US | disclosed |
| US-RE30811-E | SEROTONIN ANTAGONISTS, ANTIARRHYTHMIA AGENTS | MEAD JOHNSON & COMPANY (US) | 1981-12-01 | — | — | US | disclosed |
| US-4064254-A | ANTIARRHYTHMIC AND ANTISEROTONINE AGENTS | MEAD JOHNSON & COMPANY (US) | 1977-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070946-A1 | Hydroxymethylbenzothiazoles Amides | TPMT, SDHA, SDHB | RXRB 1657/4885RXRA 2170/4885HTT 23/4885 |
| US-20140235628-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | KCNJ11, KCNJ1, KCNJ2 | RXRB 4036/4885RXRA 4173/4885HTT 3484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.